José L Bueno, Ana B Bocanegra, Isabel Sánchez, José M Mateos, Alba Puyuelo, José A García Erce, Héctor Villanueva, María M Reaño, Lucía Núñez, Azucena Losa, Ana Arias, Miriam Aguilar, Luis A Richart, Fátima Martínez, Rosario Salgado, Ana Royuela, Juan L Cruz-Bermúdez, Roberto Fernández, Rafael Forés, Inocencia Fornet, Emilio Ojeda, Rafael Cabrera, Rafael F Duarte
BACKGROUND: Hemovigilance (HV) is usually based on voluntary reports (passive HV). Our aim is to ascertain credible incidence, severity, and mortality of transfusion-associated adverse events (TAAEs) using an active HV program. STUDY DESIGN AND METHODS: Prospective cohort study to estimate transfusion risk after 46,488 transfusions in 5830 patients, using an active HV program with follow-up within the first 24 h after transfusion. We compared these results to those with the previously established passive HV program during the same 30 months of the study...
September 15, 2023: Transfusion